{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:04Z","timestamp":1794009064058,"version":"4.8.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,11]]},"abstract":"<jats:p>\n                    Breast cancer is the most commonly diagnosed malignancy worldwide. In hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer (mBC), cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i) are the standard treatment. Sarcopenia, characterized by progressive muscle loss, is increasingly recognized as a factor influencing cancer outcomes. This study evaluated the impact of preexisting sarcopenia on overall survival, progression-free survival, and treatment-related adverse effects in patients receiving CDK4\/6i therapy. A retrospective analysis was conducted on hormone receptor-positive mBC patients treated with CDK4\/6i at Istanbul Training and Research Hospital between 2020 and 2024. Patients were classified as sarcopenic or non-sarcopenic based on pretreatment computed tomography muscle mass measurements. Survival outcomes were assessed using Kaplan\u2013Meier analysis, and treatment-related adverse effects, including dose reductions, acute kidney injury, liver function test abnormalities, and neutropenia, were compared between groups. Among 111 patients, 20 (18%) were identified as sarcopenic. Sarcopenia was associated with significantly lower overall survival and progression-free survival compared to non-sarcopenic patients (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.000). However, no significant differences were observed between groups in treatment-related adverse effects, including the need for dose reduction, acute kidney injury, liver function abnormalities, and neutropenia (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). Sarcopenia negatively impacts survival outcomes in hormone receptor-positive mBC patients receiving CDK4\/6i therapy. Routine screening and targeted interventions, such as nutritional support and physical activity programs, may help improve patient resilience and treatment efficacy. Further research is needed to develop strategies to mitigate sarcopenia\u2019s impact on survival in this patient population.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000043374","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T18:01:09Z","timestamp":1752516069000},"page":"e43374","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["The impact of sarcopenia on adverse effects and survival in patients with metastatic hormone receptor-positive breast cancer treated with CDK4\/6 inhibitors"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-3075","authenticated-orcid":false,"given":"Vahit Can","family":"Cavdar","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7015-6736","authenticated-orcid":false,"given":"Mert","family":"Aric","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Beylikduzu State Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3046-2084","authenticated-orcid":false,"given":"Ibrahim Taskin","family":"Rakici","sequence":"additional","affiliation":[{"name":"Department of Radiology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1998-3150","authenticated-orcid":false,"given":"Ilkay","family":"Gulturk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8209-0190","authenticated-orcid":false,"given":"Zekiye Busra","family":"Karaca","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Beylikduzu State Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3764-7639","authenticated-orcid":false,"given":"Cigdem Usul","family":"Afsar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6221-0623","authenticated-orcid":false,"given":"Goncagul","family":"Akdag","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Health Science University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-3632","authenticated-orcid":false,"given":"Riza Umar","family":"Gursu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4223-4940","authenticated-orcid":false,"given":"Ozgur","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-104X","authenticated-orcid":false,"given":"Basak","family":"Ballica","sequence":"additional","affiliation":[{"name":"Bahcesehir University Faculty of Medicine, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250812","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040.","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"R2-20250812","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","article-title":"Planning for tomorrow: global cancer incidence and the role of prevention 2020\u20132070.","volume":"18","author":"Soerjomataram","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R3-20250812","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: presentation, investigation and management.","volume":"83","author":"Katsura","year":"2022","journal-title":"Br J Hosp Med (Lond)"},{"key":"R4-20250812","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in breast cancer survival by molecular subtypes in the United States.","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R5-20250812","doi-asserted-by":"crossref","first-page":"1758835918786451","DOI":"10.1177\/1758835918786451","article-title":"CDK4\/6 inhibition in breast cancer: current practice and future directions.","volume":"10","author":"Pernas","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"R6-20250812","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer.","volume":"22","author":"Goel","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"R7-20250812","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis.","volume":"39","author":"Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"key":"R8-20250812","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jamda.2013.11.025","article-title":"Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia.","volume":"15","author":"Chen","year":"2014","journal-title":"J Am Med Dir Assoc"},{"key":"R9-20250812","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"R10-20250812","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.athoracsur.2019.04.090","article-title":"Computed tomography-assessed skeletal muscle mass as a predictor of outcomes in lung cancer surgery.","volume":"108","author":"Nishimura","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"R11-20250812","first-page":"221","article-title":"Reference skeletal muscle mass values at L3 Vertebrae level based on computed tomography in healthy Turkish adults.","volume":"13","author":"Ufuk","year":"2019","journal-title":"Int J Gerontol"},{"key":"R12-20250812","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribo ciclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"R13-20250812","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"R14-20250812","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/emmm.201000089","article-title":"Cycling through metabolism: cell cycle and metabolism.","volume":"2","author":"Aguilar","year":"2010","journal-title":"EMBO Mol Med"},{"key":"R15-20250812","first-page":"e170315","article-title":"CDK4 is an essential insulin effector in adipocytes.","volume":"133","author":"Lagarrigue","year":"2023","journal-title":"J Clin Invest"},{"key":"R16-20250812","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fonc.2013.00004","article-title":"Re-thinking cell cycle regulators: the cross-talk with metabolism.","volume":"3","author":"Fajas","year":"2013","journal-title":"Front Oncol"},{"key":"R17-20250812","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41467-018-03451-1","article-title":"CDK6 inhibits white to beige fat transition by suppressing RUNX1.","volume":"9","author":"Hou","year":"2018","journal-title":"Nat Commun"},{"key":"R18-20250812","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1245\/s10434-023-13569-2","article-title":"Association of sarcopenia with a poor prognosis and decreased tumor-infiltrating CD8-positive T cells in pancreatic ductal adenocarcinoma: a retrospective analysis.","volume":"30","author":"Masuda","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"R19-20250812","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12672-022-00576-0","article-title":"Impact of sarcopenia on the prognosis and treatment of lung cancer: an umbrella review.","volume":"13","author":"Lin","year":"2022","journal-title":"Discov Oncol"},{"key":"R20-20250812","first-page":"374","article-title":"Association of low muscle mass as a marker of sarcopenia with survival in metastatic renal cell carcinoma patients receiving nivolumab.","volume":"6","author":"Tacar","year":"2022","journal-title":"EJMI"},{"key":"R21-20250812","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12885-023-10582-2","article-title":"Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis.","volume":"23","author":"Luo","year":"2023","journal-title":"BMC Cancer"},{"key":"R22-20250812","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2015.04.003","article-title":"Cachexia and sarcopenia: mechanisms and potential targets for intervention.","volume":"22","author":"Argil\u00e9s","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"R23-20250812","doi-asserted-by":"crossref","first-page":"e172319","DOI":"10.1001\/jamaoncol.2017.2319","article-title":"Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study.","volume":"3","author":"Cespedes Feliciano","year":"2017","journal-title":"JAMA Oncol"},{"key":"R24-20250812","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-09-1525","article-title":"Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.","volume":"15","author":"Tan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R25-20250812","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbamcr.2011.11.003","article-title":"Multitasking in the mitochondrion by the ATP-dependent Lon protease.","volume":"1823","author":"Venkatesh","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"R26-20250812","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jgo.2018.10.009","article-title":"Sarcopenia & aging in cancer.","volume":"10","author":"Williams","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"R27-20250812","doi-asserted-by":"crossref","first-page":"e123000","DOI":"10.1172\/jci.insight.123000","article-title":"Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity.","volume":"3","author":"Iqbal","year":"2018","journal-title":"JCI Insight"},{"key":"R28-20250812","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations.","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"key":"R29-20250812","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2015.09.001","article-title":"Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes.","volume":"54","author":"Kazemi-Bajestani","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"R30-20250812","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/bjc.2016.431","article-title":"The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Cancer"},{"key":"R31-20250812","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/1078-0432.CCR-16-0940","article-title":"Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy.","volume":"23","author":"Shachar","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:01:06Z","timestamp":1755018066000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":31,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043374","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}